{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:24:17Z","timestamp":1766712257841,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-acting injectable antiretroviral (LA-ARV) drugs with low toxicity profiles and propensity for drug-drug interactions are a goal for future ARV regimens. C34-PEG<jats:sub>4<\/jats:sub>-Chol is a novel cholesterol tagged LA HIV-fusion-inhibitor (FI). We assessed pre-clinical toxicology and first-in-human administration of C34-PEG<jats:sub>4<\/jats:sub>-Chol. Pre-clinical toxicology was conducted in 2 species. HIV-positive men were randomised to a single subcutaneous dose of C34-PEG<jats:sub>4<\/jats:sub>-Chol at incrementing doses or placebo. Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacokinetic (time-to-minimum-effective-concentration (MEC, 25\u2009ng\/mL) and pharmacodynamic (plasma HIV RNA) parameters were assessed. In both mice and dogs, no-observed-adverse effect level (NOAEL) was observed at a 12\u2009mg\/kg\/dose after two weeks. Of 5 men enrolled, 3 received active drug (10\u2009mg, 10\u2009mg and 20\u2009mg). In 2 individuals grade 3 ISR occurred and the study was halted. Both ISR emerged within 12\u2009hours of active drug dosing. No systemic toxicities were observed. The time-to-MEC was &gt;72 and &gt;96\u2009hours after 10 and 20\u2009mg dose, respectively, and mean change in HIV RNA was \u22120.9 log10 copies\/mL. These human pharmacodynamic and pharmacokinetic data, although limited to 3 subjects, of C34-PEG-4-Chol suggest continuing evaluation of this agent as a LA-ARV. However, alternative administration routes must be explored.<\/jats:p>","DOI":"10.1038\/s41598-017-09230-0","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T09:57:44Z","timestamp":1503309464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol"],"prefix":"10.1038","volume":"7","author":[{"given":"Killian","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Traboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujan Dily","family":"Penchala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Bouliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicki","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Libri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-2139","authenticated-orcid":false,"given":"Antonello","family":"Pessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"9230_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji, H. et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One \n                           8, e81355, doi:10.1371\/journal.pone.0081355 (2013).","journal-title":"PLoS One"},{"key":"9230_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten, J. et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis \n                           59, 1787\u20131797, doi:10.1093\/cid\/ciu701ciu701 (2014).","journal-title":"Clin Infect Dis"},{"key":"9230_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QCO.0000000000000117","volume":"28","author":"A Winston","year":"2015","unstructured":"Winston, A. & Underwood, J. Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. Curr Opin Infect Dis \n                           28, 17\u201322, doi:10.1097\/QCO.0000000000000117 (2015).","journal-title":"Curr Opin Infect Dis"},{"key":"9230_CR4","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med \n                           348, 2175\u20132185, doi:10.1056\/NEJMoa035026 (2003).","journal-title":"N Engl J Med"},{"key":"9230_CR5","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1056\/NEJMoa035211","volume":"348","author":"A Lazzarin","year":"2003","unstructured":"Lazzarin, A. et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med \n                           348, 2186\u20132195, doi:10.1056\/NEJMoa035211 (2003).","journal-title":"N Engl J Med"},{"key":"9230_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/427993","volume":"191","author":"JP Lalezari","year":"2005","unstructured":"Lalezari, J. P. et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis \n                           191, 1155\u20131163, doi:10.1086\/427993 (2005).","journal-title":"J Infect Dis"},{"key":"9230_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032599","volume":"7","author":"H Chong","year":"2012","unstructured":"Chong, H. et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One \n                           7, e32599, doi:10.1371\/journal.pone.0032599 (2012).","journal-title":"PLoS One"},{"key":"9230_CR8","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He, Y. et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. The Journal of biological chemistry \n                           283, 11126\u201311134, doi:10.1074\/jbc.M800200200 (2008).","journal-title":"The Journal of biological chemistry"},{"key":"9230_CR9","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1002\/jps.24174","volume":"103","author":"Q Meng","year":"2014","unstructured":"Meng, Q. et al. Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients. Journal of pharmaceutical sciences \n                           103, 4038\u20134047, doi:10.1002\/jps.24174 (2014).","journal-title":"Journal of pharmaceutical sciences"},{"key":"9230_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1073\/pnas.85.3.900","volume":"85","author":"RC Aloia","year":"1988","unstructured":"Aloia, R. C., Jensen, F. C., Curtain, C. C., Mobley, P. W. & Gordon, L. M. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci USA \n                           85, 900\u2013904 (1988).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9230_CR11","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1073\/pnas.90.11.5181","volume":"90","author":"RC Aloia","year":"1993","unstructured":"Aloia, R. C., Tian, H. & Jensen, F. C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA \n                           90, 5181\u20135185 (1993).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9230_CR12","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","volume":"106","author":"P Ingallinella","year":"2009","unstructured":"Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA \n                           106, 5801\u20135806, doi:10.1073\/pnas.0901007106 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9230_CR13","doi-asserted-by":"crossref","unstructured":"Zhang, L. & Bulaj, G. Converting peptides into drug leads by lipidation. Curr. Med. Chem. 19, 1602\u20131618, doi:CDT-EPUB-20120229-002 (2012).","DOI":"10.2174\/092986712799945003"},{"key":"9230_CR14","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","volume":"106","author":"P Ingallinella","year":"2009","unstructured":"Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 Peptide Fusion Inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA \n                           106, 5801\u20135806, doi:10.1073\/pnas.0901007106 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9230_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/sim.7169","volume":"36","author":"AJ Mason","year":"2017","unstructured":"Mason, A. J. et al. Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Stat Med \n                           36, 754\u2013771, doi:10.1002\/sim.7169 (2017).","journal-title":"Stat Med"},{"key":"9230_CR16","first-page":"67","volume":"10","author":"RW Shafer","year":"2008","unstructured":"Shafer, R. W. & Schapiro, J. M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev \n                           10, 67\u201384 (2008).","journal-title":"AIDS Rev"},{"key":"9230_CR17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","volume":"72","author":"LT Rimsky","year":"1998","unstructured":"Rimsky, L. T., Shugars, D. C. & Matthews, T. J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol \n                           72, 986\u2013993 (1998).","journal-title":"J Virol"},{"key":"9230_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/COH.0000000000000164","volume":"10","author":"PE Williams","year":"2015","unstructured":"Williams, P. E., Crauwels, H. M. & Basstanie, E. D. Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV AIDS \n                           10, 233\u2013238, doi:10.1097\/COH.000000000000016401222929-201507000-00006 (2015).","journal-title":"Curr Opin HIV AIDS"},{"key":"9230_CR19","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1128\/JVI.00135-10","volume":"84","author":"M Porotto","year":"2010","unstructured":"Porotto, M. et al. Viral Entry Inhibitors Targeted to the Membrane Site of Action. J. Virol. \n                           84, 6760\u20136768, doi:10.1128\/jvi.00135-10 (2010).","journal-title":"J. Virol."},{"key":"9230_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036833","volume":"7","author":"A Pessi","year":"2012","unstructured":"Pessi, A. et al. A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity. PLoS One \n                           7, e36833 (2012).","journal-title":"PLoS One"},{"key":"9230_CR21","doi-asserted-by":"publisher","first-page":"42141","DOI":"10.1074\/jbc.M111.254243","volume":"286","author":"KK Lee","year":"2011","unstructured":"Lee, K. K. et al. Capturing a Fusion Intermediate of Influenza Hemagglutinin with a Cholesterol-conjugated Peptide, a New Antiviral Strategy for Influenza Virus. J. Biol. Chem. \n                           286, 42141\u201342149, doi:10.1074\/jbc.M111.254243 (2011).","journal-title":"J. Biol. Chem."},{"key":"9230_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001168","volume":"6","author":"M Porotto","year":"2010","unstructured":"Porotto, M. et al. Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry. PLoS Pathog. \n                           6, e1001168 (2010).","journal-title":"PLoS Pathog."},{"key":"9230_CR23","doi-asserted-by":"publisher","first-page":"13785","DOI":"10.1128\/JVI.02436-13","volume":"87","author":"JC Welsch","year":"2013","unstructured":"Welsch, J. C. et al. Fatal Measles Virus Infection Prevented by Brain-Penetrant Fusion Inhibitors. J. Virol. \n                           87, 13785\u201313794, doi:10.1128\/jvi.02436-13 (2013).","journal-title":"J. Virol."},{"key":"9230_CR24","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1016\/j.bmcl.2013.07.056","volume":"23","author":"CD Higgins","year":"2013","unstructured":"Higgins, C. D., Koellhoffer, J. F., Chandran, K. & Lai, J. R. C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: Effects of conjugation to cholesterol and side chain\u2013side chain crosslinking. Bioorg. Med. Chem. Lett. \n                           23, 5356\u20135360, doi:10.1016\/j.bmcl.2013.07.056 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"9230_CR25","doi-asserted-by":"publisher","first-page":"9223","DOI":"10.1128\/JVI.01153-13","volume":"87","author":"C-G Li","year":"2013","unstructured":"Li, C.-G. et al. A Cholesterol Tag at the N Terminus of the Relatively Broad-Spectrum Fusion Inhibitory Peptide Targets an Earlier Stage of Fusion Glycoprotein Activation and Increases the Peptide\u2019s Antiviral Potency In Vivo. J. Virol. \n                           87, 9223\u20139232, doi:10.1128\/jvi.01153-13 (2013).","journal-title":"J. Virol."},{"key":"9230_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/psc.2706","volume":"21","author":"A Pessi","year":"2015","unstructured":"Pessi, A. Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases. J. Pept. Sci. \n                           21, 379\u2013386, doi:10.1002\/psc.2706 (2015).","journal-title":"J. Pept. Sci."},{"key":"9230_CR27","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge, W. M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow. Metab. \n                           32, 1959\u20131972, doi:10.1038\/jcbfm.2012.126 (2012).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"9230_CR28","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1021\/jm070861j","volume":"50","author":"K Madsen","year":"2007","unstructured":"Madsen, K. et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. \n                           50, 6126\u20136132 (2007).","journal-title":"J. Med. Chem."},{"key":"9230_CR29","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/db09-0278","volume":"58","author":"A Pocai","year":"2009","unstructured":"Pocai, A. et al. Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice. Diabetes \n                           58, 2258\u20132266, doi:10.2337\/db09-0278 (2009).","journal-title":"Diabetes"},{"key":"9230_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/psc.1328","volume":"17","author":"A Santoprete","year":"2011","unstructured":"Santoprete, A. et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J. Pept. Sci. \n                           17, 270\u2013280, doi:10.1002\/psc.1328 (2011).","journal-title":"J. Pept. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09230-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:26:23Z","timestamp":1671787583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09230-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9230"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09230-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"assertion":[{"value":"27 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T., A.N., R.C. and A.P. worked for J.V. Bio. All other authors have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9447"}}